Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01050985 · ClinicalTrials.gov registry record · Phase 1
A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
A Phase 1 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT01050985 is a Phase 1 study that has completed, run by Georgetown University. The registered enrollment target is 47 participants.
The verdict
NCT01050985, a Phase 1 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
This study is for people with advanced cancer for which no curative treatment exists. The purpose of this study is to test the safety and effectiveness of the combination of the drugs Temsirolimus and Capecitabine and see what effects it has on cancer. Temsirolimus is a drug that is given by vein that targets a protein important for the growth of cancer cells known as mTOR. By inhibiting this protein, Temsirolimus can inhibit cancer cell growth and even lead to their death. Capecitabine is a more traditional chemotherapy. It is an oral pill that gets converted in the body to the very common chemotherapy known as 5-fluorouracil. This research is being done because it is not known if the combination of Temsirolimus and Capecitabine will work better than Capecitabine or Temsirolimus alone.
Interventions
- DRUG Temsirolimus and capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2010-07 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01050985
The ClinicalTrials.gov registry entry for NCT01050985 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Temsirolimus and capecitabine is the first listed.
NCT01050985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01050985 about?
NCT01050985 is a clinical study titled "A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer". This study is for people with advanced cancer for which no curative treatment exists. The purpose of this study is to test the safety and effectiveness of the combination of the drugs Temsirolimus and Capecitabine and see what effects it has on cancer. Temsirolimus is a drug that is given by vein ...
What is the current status of trial NCT01050985?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2010-07. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01050985?
The interventions under investigation include: Temsirolimus and capecitabine (DRUG).
Who is sponsoring clinical trial NCT01050985?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.